A new medication is showing positive results in terms of clinical response and remission for those with moderate to severe Crohn’s disease.
Janssen Pharmaceuticals’ drug candidate Stelara (ustekinumab) demonstrated positive therapeutic effects in a recent Phase 3 clinical trial, inducing clinical response and remission in adult patients with moderate to severe Crohn’s disease who had been treated with anti-tumor necrosis factor (TNF)-alpha therapy and were either unresponsive or intolerant to it.
The efficacy and safety results from the Second Stelara Phase 3 Induction Study (UNITI-1) were presented at the 11th Congress of the European Crohn’s and Colitis Organization. Janssen has submitted applications, currently under review, with the U.S. FDA and the European Medicines Agency seeking approval of Stelara for the treatment of moderate to severe Crohn’s disease.
Stelara is a monoclonal antibody antagonist of human interleukin-12 and interleukin-23, molecules that are believed to play a role in the autoimmunity that leads to diseases such as Crohn’s.
The placebo-controlled UNITI-1 study enrolled 741 adult patients with moderate to severe Crohn’s disease who were randomized to receive either a single IV infusion of placebo, Stelara 130 mg, or Stelara ~6 mg/kg. The study’s primary endpoint was the clinical response at week six, measured through the reduction by at least 100 points in the Crohn’s Disease Activity Index (CDAI) score. Secondary endpoints included, at week eight, clinical response and clinical remission.
|Read Full Article: Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results | IBD News Today|